Celldex Therapeutics, Inc. insider trading
Every open-market purchase and sale by Celldex Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Celldex Therapeutics, Inc.’s insiders pay?
From September 9, 2010 to December 8, 2025, 17 insiders reported 22 open-market purchases and 27 sales not made under a pre-set plan in Celldex Therapeutics, Inc. Twelve months after each purchase was reported, the shares were +44.6% against the S&P 500 on average (median −13.4%), over 12 purchases with a full year of prices; 42% beat the index. After sales, the shares moved −29.3% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 17, 2015 into $6,746 by November 2, 2026, −3.5% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,703 (+6.7% a year), and held throughout $43,193 (+14.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO | 5 | +38.9% (3) | 33% | 1 | −15.0% (1) | November 12, 2024 |
| Ellberger Larry | Director | 4 | −83.9% (4) | 0% | 1 | −34.0% (1) | August 26, 2015 |
| Martin Samuel Bates | SVP AND CFO | 1 | +210.9% (1) | 100% | 4 | −34.1% (4) | June 18, 2024 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | 1 | −10.8% (1) | 0% | 3 | −2.6% (2) | December 8, 2025 |
| Keler Tibor | EXECUTIVE VP & CSO | 3 | +210.9% (1) | 100% | 1 | −30.3% (1) | December 9, 2022 |
| Wright Richard M. | SR. VP & CCO | 0 | — | — | 4 | +2.1% (3) | November 17, 2025 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | 1 | +132.2% (1) | 100% | 3 | −27.9% (3) | June 11, 2024 |
| Crowley Elizabeth | SR. VP & CPDO | 0 | — | — | 3 | −52.6% (3) | June 18, 2024 |
| Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | 0 | — | — | 2 | −35.0% (2) | June 3, 2024 |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | 0 | — | — | 2 | −52.2% (2) | June 5, 2024 |
| Marino James J | Director | 2 | +210.9% (1) | 100% | 0 | — | June 10, 2020 |
| Penner Harry Jr | Director | 1 | — | — | 1 | −34.0% (1) | December 10, 2013 |
| Shoos Karen L. | Director | 1 | — | — | 1 | −34.0% (1) | December 10, 2013 |
| Catlin Avery W | Sr. VP & CFO | 0 | — | — | 1 | −34.0% (1) | December 10, 2013 |
| Parekh Rajesh B | Director | 1 | — | — | 0 | — | September 14, 2010 |
| Schaller Charles R | Director | 1 | — | — | 0 | — | September 13, 2010 |
| Shannon Timothy M | Director | 1 | — | — | 0 | — | September 13, 2010 |
When several insiders traded Celldex Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Celldex Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −17.6% against the index. After 3 selling crowds, −8.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 28, 2024 | 7 selling | −15.6% | −41.4% | −55.7% |
| August 31, 2022 | 5 selling | +18.4% | +50.7% | −21.3% |
| June 30, 2020 | 5 buying | +8.6% | +10.5% | +116.3% |
| August 31, 2015 | 2 buying | +15.2% | −45.8% | −89.6% |
| December 31, 2013 | 4 selling | −29.2% | −35.2% | −38.1% |